VANCOUVER, British Columbia, May 4, 2007 – The University of British Columbia (UBC) and ARC Pharmaceuticals Inc. (ARC) today announced that key patents relating to ARC's lead product candidate, Arcad Instillate, for the prevention and treatment of surgical adhesions, were recently issued or granted in several territories. The patents are assigned to UBC and ARC previously in-licensed these technologies through an exclusive worldwide license agreement with UBC.
USA Patent # 7,163,930, Australia Patent # 2002325113 and New Zealand Patent # 532015 were recently issued and China Patent # 02816693.0 was granted and will be registered in Hong Kong. These patents are in addition to the earlier issued USA Patent # 6,812,220 and a portfolio of related patent applications in additional territories. The patents relate to the use of fucans including fucoidan for the prevention and treatment of surgical adhesions and/or fibrous adhesions. Fucoidan is the key component of ARCAD™ Instillate.
ARC has demonstrated in several different preclinical models of surgical adhesions that the use of ARCAD™ Instillate resulted in a significant reduction in the number and severity of post-surgical adhesions,” said Chris Springate, President and CEO of ARC.
About ARCAD™ technology – The key component of ARCAD™ Instillate is a fucan known as fucoidan. Fucoidan is a naturally occurring polysaccharide and is extracted from seaweed or brown marine algae. ARC has purified and incorporated fucoidan into the Company's proprietary lead product candidate, ARCAD™ Instillate, for the prevention of surgical adhesions. ARC has also commenced exploration of the use of the ARCAD™ technology in other disease indications and has formulated ARCAD™ as a gel and as a film.
About ARC Pharmaceuticals Inc. – ARC Pharmaceuticals Inc. is developing innovative medical products for the prevention and treatment of surgical adhesions, a major complication in a high proportion of common surgical procedures. Further potential opportunities exist for the technology in the management of arthritis and psoriasis.
Statements contained in this press release that are not based on historical fact, including without limitation statements containing the words "will", "plans", "could", "may", "expects", "intends", "anticipates", "continue", "estimate" and similar expressions constitute "forward-looking statements". All such statements are made pursuant to the "safe harbor" provisions of applicable securities legislation. Forward-looking statements may involve without limitation comments with respect to the Company's research and development and commercialization objectives including product candidates for surgical adhesions, arthritis and psoriasis, intellectual property including patents, and business strategies and objectives. Forward-looking statements involve known and unknown risks and uncertainties including risks and uncertainties beyond the Company's control, which may cause the actual results to be materially different from any future results expressed or implied by forward-looking statements. Given these risks, uncertainties and assumptions, readers are cautioned not to place undue reliance on forward-looking statements and the Company claims not to be under any obligation to update or announce the result of any revisions to any forward-looking statements to reflect future results.
Contact Information:
Chris Springate President and CEO ARC Pharmaceuticals Inc. Tel: 604-222-9577 Fax: 604-222-9578
cspringate@arcpharma.com www.arcpharma.com
No comments:
Post a Comment